Quanta secures $245m to market haemodialysis system
The funding proceeds will be used to expand international operations with a focus on the US market.
Nephrology & Urology
Biocept and Quest Diagnostics partner on lung cancer biopsy test
The partnership will use Biocept's less invasive, lab-developed assay to conduct genomic profiling in advanced...
Novo Holdings acquires BBI Group from Exponent for $564m
BBI Group has more than 400 employees at sites spanning seven countries and four continents.
Olympus acquires Israeli medical device firm Medi-Tate
With the Medi-Tate acquisition, Olympus will gain ownership of iTind, a temporarily implanted nitinol device...
BD treats first subjects in study of WavelinQ system for fistula creation
Becton, Dickinson and Company (BD) has treated the first subjects with the WavelinQ EndoAVF System...
CLEP approves biomarker assays from Eurofins and Transplant Genomics
The New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved two non-invasive tests from Eurofins Viracor and Transplant Genomics that aid clinicians in analysing rejection status in kidney transplant recipients.
Vagus nerve stimulation sheds light on tackling obesity
Researchers have developed an implantable device which stimulates the endings of the vagus nerve to provide a feeling of fullness. It could one day provide a less invasive alternative to gastric bypass surgery. Natalie Healey...
Medtronic drug-coated balloon shows effectiveness in lesions treatment
Medtronic has reported that results from the study of its IN.PACT AV drug-coated balloon (DCB) showed sustained and superior effectiveness for two years in treating arteriovenous fistulae (AVF) lesions.
My Health Logic to acquire LOC technology for kidney disease diagnosis
My Health Logic, a subsidiary of Health Logic Interactive, has entered a licence agreement with an arm’s length third party (licensor) to acquire a global, exclusive licence to the UAL-Chip, a lab-on-chip (LOC) technology for...
Boston Scientific to pay US states for deceptive mesh devices marketing
Boston Scientific has agreed to pay $188.7m to settle claims made by most US states that it misled consumers on the risks of using its surgical mesh devices by deceptive marketing.
Boston Scientific returning to form with second major 2021 acquisition
Boston Scientific has bought Israeli medtech Lumenis’s surgical portfolio in a £1.07bn cash deal, its second major acquisition of 2021. After a rough 2020, Boston Scientific is looking to set itself up for the year...
